Please assess the completion status of the following clinical trial:

Trial Title: Japanese BAY88-8223 Monotherapy Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have received docetaxel or not eligible for the first course of docetaxel, i.e. patients who are not fit enough and willing.~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Multiple bone metastases~* Either regular (not occasional) analgesic medication use for cancer-related bone pain or treatment with external beam radiotherapy (EBRT) for bone pain.~* Best standard of care(BSoC) is regarded as the routine standard of care.~Exclusion Criteria :~* Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period~* History of visceral metastasis, or presence of visceral metastasis

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).